UNASSIGNED: The aim of the present study was to investigate the expression of @entity16981 ( @entity16981 ) in the primary foci and metastatic lymph nodes of @entity11 , and to analyze the function of @entity16981 in the lymph node metastases from @entity11 . The study included 93 cases of surgically resected and pathologically confirmed @entity11 , form @entity1 treated at Huaihe Hospital of Henan University (Kaifeng, China). The following clinical data was obtained from each @entity1 : Gender, age, subjective symptoms ( @entity1296 , @entity10 , a feeling of pressure in the head, etc.), site of disease, @entity5 type, pathological stage, degree of differentiation and lymph node involvement. The surgically resected @entity11 and dissected cervical lymph nodes were immunohistochemically stained, and DNA was extracted from the @entity5 and lymph node tissues samples for polymerase chain reaction sequencing and amplification. The expression of @entity16981 in the primary foci and metastatic lymph nodes of @entity11 was examined. Additionally, the association between pathological features and the postoperative survival rate of the @entity1 was analyzed. The primary lesions of all 93 cases exhibited positive @entity16981 expression and 43/157 (27.39%) lymph nodes exhibited positive @entity16981 expression. Factors that significantly influenced the postoperative survival rate of the @entity1 , included the @entity3 of the cervical lymph nodes (P<0.01), the number of dissected cervical lymph nodes (P<0.01) and the degree of differentiation (P<0.05). The @entity3 of the cervical lymph nodes was the only independent risk factor affecting postoperative disease-free survival. The risk of recurrence in @entity1 with @entity3 of the cervical lymph nodes was 6.3-fold higher than in those without @entity3 (P<0.01). Thus, the results of the present study provide a theoretical basis for accurately predicting the prognosis of @entity1 with low-grade malignant @entity13 , reducing the conjecture involved in selecting postoperative treatment strategies and improving therapeutic efficacy.

Expression of XXXX in lymph node @entity3 from @entity11 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity13 :: ('MESH:C564230', 'Disease') :: ['brain glioma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity16981 :: ('7298', 'Gene') :: ['thymidylate synthase', 'TYMS'] @entity11 :: ('MESH:D005910', 'Disease') :: ['low-grade glioma', 'gliomas'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']
@entity16981 :: (7298,Gene) :: ['TYMS']
